Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate.
Among the bisphosphonates (BPs), the aminobisphosphonates (aminoBPs) have much stronger bone-resorption-inhibitory activities (BRIAs) than nonaminobisphosphonates (nonaminoBPs). However, aminoBPs have inflammatory effects. We previously reported that in mice: (i) all aminoBPs tested (10-40 micromol/kg) induced various inflammatory reactions (including induction of histidine decarboxylase), whereas clodronate (a non-aminoBP) (10-160 micromol/kg) inhibited these reactions; and (ii) a clear sclerotic line (tentatively called the BP line) was detectable in the tibia by radiography a few weeks after a single injection of either alendronate (a typical aminoBP) (1.6 micromol/kg) or clodronate (160 micromol/kg), and this BP-line formation (a marker for the BRIAs of BPs) was not reduced in mice given both alendronate and clodronate. In this study, using this murine model, we compared clodronate, etidronate (another typical non-aminoBP), alendronate, etidronate + alendronate, and clodronate + alendronate in terms of their inflammatory effects and/or BP-line formation. For BP-line formation, 480 micromol/kg etidronate was needed (single injection). At 160 micromol/kg, etidronate inhibited the histidine decarboxylase induction, but not the other inflammatory reactions induced by alendronate. However, etidronate (unlike clodronate) also inhibited alendronate-induced BP-line formation (even at 40 micromol/kg). Etidronate (160 micromol/kg) also inhibited the physicochemical changes in the tibia induced by six, weekly injections of alendronate. Therefore, depending on the dose, etidronate can inhibit alendronate's inflammatory actions and its BRIA. These results, together with those reported previously, suggest that a strategy utilizing clodronate (but not etidronate) plus an aminoBP might prevent or reduce the inflammatory side effects induced by aminoBPs while preserving their powerful BRIAs. We discuss the mechanisms underlying the antagonism between aminoBPs and non-aminoBPs.
Funayama
H
H
Department of Molecular Regulation, Graduate School of Dentistry, Tohoku University, Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan.
Ohsako
M
M
Monma
Y
Y
Mayanagi
H
H
Sugawara
S
S
Endo
Y
Y
D019386:Alendronate / Q000009:adverse effects*; D000818:Animals; D000893:Anti-Inflammatory Agents; D000963:Antimetabolites / Q000494:pharmacology; D001862:Bone Resorption / Q000517:prevention & control*; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D004002:Clodronic Acid / Q000494:pharmacology*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000494:pharmacology*; D006640:Histidine Decarboxylase / Q000187:drug effects; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C
D000893:Anti-Inflammatory Agents; D000963:Antimetabolites; D004002:Clodronic Acid; D006640:Histidine Decarboxylase; D012968:Etidronic Acid; D019386:Alendronate